Praxis Precision Medicines Earnings Call Transcripts
Fiscal Year 2026
-
NDA for Ulyxa submitted with standard review to optimize economic and regulatory outcomes, with launch preparations including disease awareness, specialty pharmacy, and a large sales force. Pipeline progress includes relumitragene for rare epilepsy, vormetragine for focal seizures, and ongoing phase III for elsunersen.
-
Significant unmet need in essential tremor and epilepsy is being addressed with new therapies, with two NDAs on track for mid-February filing. Commercial strategy includes robust sales force, targeted outreach, and pricing in the $40,000–$60,000 range. Cash reserves support launches into 2028.
Fiscal Year 2025
-
Major clinical and regulatory milestones achieved in 2025, including two NDA submissions and strong pivotal data across the CNS portfolio. Financial position strengthened with $1.5B in cash, supporting multiple commercial launches and pipeline progress into 2028.
-
The discussion provided an in-depth review of the Essential Three program's statistical rigor, addressing concerns about endpoint changes, missing data, and sensitivity analyses. Robustness was demonstrated through multiple methods, with consistent, highly significant results across primary and secondary endpoints.
-
Key programs include a successful essential tremor study with NDA filing expected early next year and advancing epilepsy assets, notably relutrigine for rare DEEs. Commercial plans target a large US market, and regulatory alignment with the FDA is strong.
-
Two NDAs are expected to be filed in the next three to six months, targeting essential tremor and rare epilepsies, with strong clinical data and ongoing FDA engagement. Market opportunities are significant, with peak sales for essential tremor projected at $10–15 billion globally.
-
Recent advances in clinical development and regulatory strategy are accelerating timelines for rare epilepsy and essential tremor therapies, with robust efficacy and safety data supporting early NDA filings and premium pricing. Patient-centric recruitment and commercial insights are driving rapid progress.
-
Ulixacaltamide met all primary and key secondary endpoints in two phase III studies for essential tremor, showing robust efficacy and a favorable safety profile. Regulatory preparations are advanced, and the drug is positioned to address a significant unmet need in a large patient population.
-
Vormatrigene’s strong efficacy and tolerability data have energized clinicians, with rapid progress in pivotal trials and operational improvements supporting accelerated timelines. Relutrigine’s breakthrough results and regulatory momentum position it for near-term NDA submission and significant market impact.
-
The IEC conference highlighted strong engagement and enthusiasm for new epilepsy treatments, with RADIANT study data showing rapid and sustained seizure reduction and a favorable safety profile. Ongoing and upcoming studies, including POWER1, POWER2, EMBOLD, and elsunersen, are progressing well, with key data readouts and regulatory milestones expected over the next 12–18 months.
-
The discussion highlighted robust efficacy and safety data for Vormatrigine in refractory epilepsy, with linear PK supporting dose escalation and strong site/patient engagement. Upcoming data in generalized epilepsy and further trials are expected to reinforce its market potential.
-
The discussion highlighted strong efficacy and tolerability for relutrigine in refractory epilepsy, even among patients on multiple background therapies. Ongoing and future studies aim to position the drug as both an add-on and monotherapy, with key data updates expected at IEC and AES.
-
RADIANT study of PRAX-562 in refractory focal epilepsy showed >56% median seizure reduction, 60% responder rate, and favorable safety, even in patients on aggressive background regimens. Cash runway extends into 2028, with multiple pivotal studies and readouts ahead.
-
Vormatrigine and relutrigine are advancing through pivotal studies, with major readouts expected mid-year and by early next year. EMBOLD results showed unprecedented seizure reduction, and a robust pipeline includes ASO and essential tremor programs.
-
Four late-stage programs are advancing with key data readouts expected in the next 12–18 months, including pivotal studies for epilepsy and essential tremor. Rapid trial enrollment and robust trial design support a balanced approach to speed and data quality.
-
Significant progress across neurology programs, with relutrigine showing deepening seizure reduction and a strong safety profile, and Elsunersen advancing rapidly in clinical development. Recruitment is robust, financial runway extends into 2028, and the pipeline is expanding into new genetic targets.
-
Management highlighted strong capitalization, robust clinical pipeline progress, and strategic risk mitigation in manufacturing. Key epilepsy and DEE studies are on track, with major data readouts and an analyst event expected within the next year.
-
Multiple late-stage CNS programs leverage genetic insights, with relutrigine showing strong efficacy and safety in epilepsy. Broader DEE and focal epilepsy studies are progressing, with key data readouts expected this year and next. Essential tremor program discontinued after futility analysis.
-
Relutrigine is positioned to address a broad DEE population with a differentiated sodium channel modulation approach, showing strong early efficacy and safety data. Multiple assets are advancing through clinical development, with key milestones expected next year, and strategic partnerships like UCB validating the pipeline.
-
Multiple late-stage CNS assets are advancing, with key epilepsy programs (Vormatrigine, Relutrigine, Elsunersen) showing strong efficacy and safety. Several pivotal trial readouts are expected within the next 12–18 months, targeting large unmet needs and significant market opportunities.
-
Relutrigine demonstrated robust efficacy and safety in severe epilepsy, with long-term benefits and a differentiated mechanism. Multiple late-stage studies are progressing, including for DEEs and focal/generalized seizures, with key data readouts expected in 2024–2025. Ongoing regulatory engagement supports broad expansion and rapid enrollment.
-
Four late-stage CNS assets are advancing, with a pivotal essential tremor program using improved endpoints and robust patient interest. Relutrigine shows strong efficacy in rare epilepsy, with broader trials and NDA filing planned for 2026. Cash reserves of $470M fund operations into 2028.
-
Four assets have advanced to registrational phase, including the first-ever phase III essential tremor trial and three late-stage epilepsy programs. Key data readouts for essential tremor and epilepsy are expected in 2024, with NDA filings targeted for 2025 and 2026.
-
Four late-stage CNS programs are advancing, with imminent Phase 3 readouts in essential tremor and epilepsy. Innovative trial designs, strong regulatory alignment, and robust patient engagement support NDA filings through 2028, targeting large unmet needs and significant revenue potential.
Fiscal Year 2024
-
Multiple late-stage clinical programs are advancing, with key readouts for essential tremor and epilepsy expected in 2025. Confidence is high due to strong data, execution, and market opportunity, with commercial and regulatory strategies in place for rapid progression.
-
Significant unmet need in essential tremor is driving high trial participation for ulixacaltamide, which shows strong differentiation and promising phase II results. Vormatrigine and relutrigine are advancing in epilepsy and DEEs, with multiple pivotal readouts expected in 2024–2026.
-
Four CNS drugs are in clinical development, with two phase III studies for essential tremor using innovative designs and an interim analysis planned for Q1. Epilepsy assets show strong preclinical and clinical data, with a focus on safety, efficacy, and broad commercial potential.
-
Four late-stage programs are advancing, with strong phase II data in epilepsy and essential tremor. Cash runway extends into 2027, supporting multiple pivotal readouts and an NDA filing in 2025.
-
Multiple late-stage clinical programs advanced, including two phase III studies for ulixacaltamide and registrational studies for PRAX-628, relutrigine, and elsanorisen. Interim analyses, robust trial designs, and recent capital raises support a focused strategy, with key data readouts expected through 2025.
-
The EMBOLD study in pediatric DEE patients with SCN2A and SCN8A mutations showed a 46% placebo-adjusted seizure reduction and unprecedented seizure freedom, with relutrigine demonstrating strong efficacy, safety, and tolerability. Long-term data revealed a 75% median seizure reduction, supporting rapid advancement to registration studies.
-
Four late-stage clinical programs are advancing, with key readouts for essential tremor, epilepsy, and DEE expected in the next year. Strong cash reserves support operations into 2027, and interim analyses may optimize trial success and timelines.
-
Significant progress was made in advancing late-stage clinical programs for essential tremor and epilepsy, with strong patient demand and robust trial designs. The pipeline is diversified, with promising assets in epilepsy and developmental encephalopathies, and capital is managed with strict discipline.